Aurinia Pharmaceuticals Inc., commonly referred to as Aurinia, is a biopharmaceutical company headquartered in Canada. Founded in 2013, Aurinia focuses on developing innovative therapies for autoimmune diseases, with a particular emphasis on lupus nephritis. The company has made significant strides in the industry, notably with the launch of its flagship product, LUPKYNIS™ (voclosporin), which offers a unique mechanism of action that enhances treatment options for patients. With a strong presence in North America and expanding operations in Europe, Aurinia has established itself as a leader in the autoimmune disease sector. The company’s commitment to research and development, coupled with its strategic partnerships, has positioned it favourably in the market, earning recognition for its contributions to patient care and treatment advancements.
How does Aurinia's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Aurinia's score of 27 is lower than 55% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Aurinia Pharmaceuticals Inc. reported total carbon emissions of approximately 218,430 kg CO2e. This figure represents the company's global emissions, with no specific data disclosed for Scope 1 or Scope 3 emissions. In the previous year, 2022, Aurinia's emissions were primarily from Scope 2, totalling about 198,740 kg CO2e, while Scope 1 emissions were recorded at zero. Aurinia has not set specific reduction targets or initiatives as part of its climate commitments, nor does it participate in initiatives such as the Science Based Targets initiative (SBTi). The company’s emissions data is not cascaded from a parent organization, indicating that these figures are independently reported. Overall, Aurinia's emissions profile reflects a focus on managing its Scope 2 emissions, with a commitment to transparency in its reporting, although further climate action initiatives or reduction targets have yet to be established.
Access structured emissions data, company-specific emission factors, and source documents
| 2022 | |
|---|---|
| Scope 1 | - |
| Scope 2 | 198,740 |
| Scope 3 | - |
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Aurinia has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
